{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-007744","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.873702+00:00","generated_at":"2026-05-21T09:51:36.283745+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Gain Therapeutics Q1 net loss $0.16/share; Phase 1b of GT-02287 enrollment underway","bullets":["Net loss per share $0.16 (basic/diluted) vs $0.22 prior year; cash $9.1M as of March 31, 2025.","R&D expenses $2.3M (down $0.2M), G&A expenses $2.1M (up $0.2M) compared to Q1 2024.","Phase 1b study of GT-02287 for Parkinson's disease initiated; first biomarker analysis expected mid-2025.","Gene Mack appointed CEO effective Jan 6, 2025; Gianluca Fuggetta assumed SVP Finance and PFO role.","IND submission to FDA expected by year end 2025; Phase 1b completion expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-007744","json":"https://secwatch.observer/filing/0001558370-25-007744.json","markdown":"https://secwatch.observer/filing/0001558370-25-007744.md","text":"https://secwatch.observer/filing/0001558370-25-007744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000155837025007744/0001558370-25-007744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000155837025007744/ganx-20250514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:51:36.283745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}